Drug Vehicle for Blindness PreventionA group of researchers from the private sector created a drug vehicle to avoid risks and painful treatments in people with blindness secondary to chronic degenerative diseases, such as diabetic retinopathy and degenerative eye diseases. This formula is great news as it eliminates the need to administer the drug through intraocular injection.

It is a product based on nanotechnology. It works with latest generation liposome particles concentrated in drops. This particles function as vehicle that wraps proteins or antibody fragments, allowing them to get into the eye. Once inside, they release the drugs.

With the nanotechnology product, costs are reduced by 80 or 90 percent and more people can use it. “With this technology hospitals do not have to allocate resources to delivery medications, as it does not require a facility and a specialist to apply it. It is necessary a physician to prescribe it; the eye drops are acquired by prescription and they are applied at home, lowering the cost,” said Juan Carlos Altamirano Vallejo, Medical Director of the Center for Medical and Surgical Retina.

Vallejo Altamirano mentioned that conditions originated in the retina are mostly caused by various chronic degenerative diseases, such as diabetes (diabetic retinopathy) or macular degeneration. Patients suffering from these diseases require, usually, one injection per month at a very high cost, which increases if the procedure is applied in both eyes.

The company, located in Jalisco, Mexico, was awarded the National Prize for Technology and Innovation (PNTI) for this product. Currently, they are conducting clinical investigations regulated by the Federal Commission for Protection Against Health Risks (COFEPRIS), and plan to conclude them next year. The idea is that the drug can be distributed in institutions of social and private security. So far, the results have shown the same efficacy than those obtained with intraocular injection, but without the inherent risks of this procedure as infection or retinal detachment. Also, patients who followed the treatment in the United States have had satisfactory results.


Source: Agencia ID